Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02988986
Title TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.

estrogen-receptor positive breast cancer


Sapanisertib + Tamoxifen

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Houston Methodist Hospital Houston Texas 77030 United States Details
Houston Methodist Hospital Willowbrook Houston Texas 77070 United States Details
Houston Methodist Hospital Sugar Land Sugar Land Texas 77479 United States Details
*Shaded cells indicate that there was no data available from for the field